News
September 23, 2026
BoomRay and Novartis Pharma sign $900m deal for radioligand therapy
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.
-
-
-
-
-
November 17, 2010
NovAliX takes over majority stake in Graffinity Pharma
Strasbourg, France-based NovAliX Group is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing. Heidelberg, Germany-based
-
-
-
November 17, 2010
Nautilus Neurosciences, Tribute Pharma sign Cambia commercialisation pact
Nautilus Neurosciences and Tribute Pharma claimed that a new, water-soluble, buffered diclofenac potassium powder – Cambia is the only prescription non – steroidal anti-inflammatory drug (NSAID) available for
-
-
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.